Effects of piracetam alone and in combination with antiepileptic drugs in rodent seizure models

Journal of Neural Transmission

Volumn 111, Issue 9, 2004, Pages 1121-1139

  Fischer, W ^a   Kittner, H ^a   Regenthal, R ^a   Russo, E ^b   De Sarro, G ^b  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Anticonvulsants; Antiepileptic drugs; Nootropic drugs; Piracetam; Seizure models

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; DIAZEPAM; ETHOSUXIMIDE; LAMOTRIGINE; NOOTROPIC AGENT; PHENOBARBITAL; PHENYTOIN; PIRACETAM; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; BRAIN DEPTH STIMULATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; DRUG TOLERABILITY; ELECTRIC SHOCK; EPILEPSY; EXPERIMENTAL MODEL; FOCAL EPILEPSY; HIPPOCAMPUS; INCIDENCE; LETHARGY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; RODENT; SEIZURE; SPIKE WAVE; TONIC SEIZURE;

ACTION POTENTIALS; ANIMALS; ANTICONVULSANTS; BRAIN; COBALT; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; DRUG SYNERGISM; ELECTROSHOCK; EPILEPSY; EPILEPSY, ABSENCE; HIPPOCAMPUS; MALE; MICE; MICE, INBRED DBA; NEUROPROTECTIVE AGENTS; PHENOBARBITAL; PHENYTOIN; PIRACETAM; VALPROIC ACID;

EID: 4544304001     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00702-004-0155-6     Document Type: Article

References (70)

1. 3H-glutamate sites. Arzneimittelforsch/ Drug Res 35 (II): 1350-1352
2. Benešová O (1980) The effects of nootropic drugs on the susceptibility to audiogenic seizures in rats. Activ Nerv Sup (Praha) 22: 192-193
3. Brunbech L, Sabers A (2002) Effect of antiepileptic drugs on cognitive function in individuals with epilepsy. A comparative review of newer versus older agents. Drugs 62: 593-604
4. Chaudhry HR, Najam N, De Mahieu C, Raza A, Ahmad N (1992) Clinical use of piracetam in epileptic patients. Curr Ther Res 52: 355-360
5. Corda MG, Orlandi M, Lecca D, Carboni G, Frau V, Giorgi O (1991) Pentylenetetrazol-induced kindling in rats: effect of GABA function inhibitors. Pharmacol Biochem Behav 40: 329-333
6. De Deyn PP, De Reuck J, Deberdt W, Vlietinck R, Orgogozo J-M (1997) Treatment of acute ischemic stroke with piracetam. Stroke 28: 2347-2352
7. De Sarro GB, Meldrum BS, Nisticò G (1988) Anticonvulsant effects of some calcium entry blockers in DBA/2 mice. Br J Pharmacol 93: 247-256
8. Dlabač A, Krejčí I, Kupková B (1981) The interaction of nootropic drugs with anticonvulsants. Activ Nerv Sup (Praha) 23: 218-219
9. Fedi M, Reutens D, Dubeau F, Andermann E, D'Agostino D, Andermann F (2001) Long-term efficacy and safety of piracetam in the treatment of progressive myoclonus epilepsy. Arch Neurol 58: 781-786
10. Fifková E, Maršala J (1967) Stereotaxic atlases for the cat, rabbit and rat. In: Bureš J, Petráň M, Zachar J (eds) Electrophysiological methods in biological research. Appendix I, 3rd rev edn. Acad Publ House Czechoslovak Acad Sci, Prague, pp 653-731
11. Fischer J, Holubář J, Malík V (1967) A new method of producing chronic epileptogenic cortical foci in rats. Physiol Bohemoslov 16: 272-277
12. Fischer W, Kittner H, Schubert S (1991) Zur Wirksamkeit von Piracetam, Meclofenoxat und Vinpocetin in verschiedenen Krampfmodellen bei der Maus. Pharmazie 46: 359-360
13. Fischer W, Bodewei R, VonVoigtlander PF, Müller M (1993) Anticonvulsant and related effects of U-54494A in various seizure tests. J Pharmacol Exp Ther 267: 163-170
14. Fischer W, Kittner H, Regenthal R, Malinowska B, Schlicker E (2001) Anticonvulsant and sodium channel blocking activity of higher doses of clenbuterol. Naunyn Schmiedebergs Arch Pharmacol 363: 182-192
15. Flicker L, Grimley EJ (2002) Piracetam for dementia or cognitive impairment (Cochrane review). Cochrane Database Syst Rev 4: CD001011
16. Genkova-Papasova M, Lazarova-Bakarova M (1992) Effects of nootropic drugs of pentylenetetrazol kindling in rats. Behav Pharmacol 3 [Suppl 1]: 78
17. Gouliaev AH, Senning A (1994) Piracetam and other structurally related nootropics. Brain Res Rev 19: 180-222
18. Hawkins CA, Mellanby JH (1986) Piracetam potentiates the antiepileptic action of carbamazepine in chronic experimental limbic epilepsy. Acta Neurol Scand 74 [Suppl 109]: 117-121
19. Helmstaedter C, Kurthen M (2001) Memory and epilepsy: characteristics, course, and influence of drugs and surgery. Curr Opin Neurol 14: 211-216
20. Hitzenberger G, Rameis H, Manigley C (1998) Pharmacological properties of piracetam. CNS Drugs 9 [Suppl 1]: 19-27
21. B receptor activation in absence seizures of lethargic (lh/lh) mice. Science 257: 398-401
22. Israel L, Melac M, Milinkevitch D, Dubos G (1994) Drug therapy and memory training programs: a double-blind randomised trial of general practice patients with age-associated memory impairment. Int Psychogeriat 6: 155-170
23. Kästner I, Müller M, Rougerie A (1972) Vergleichende tierexperimentelle Untersuchungen zur Erzeugung chronischer epileptiformer Herdaktivität. Psychiat Neurol Med Psychol 24: 581-586
24. Keller G (1991) Anticonvulsive effects of piracetam, meclofenoxate and vinpocetine on acute and kindled pentylenetetrazole (PTZ) induced seizures. Naunyn Schmiedebergs Arch Pharmacol 343 [Suppl]: R112
25. Kellogg C (1976) Audiogenic seizures: relation to age and mechanisms of monoamine neurotransmission. Brain Res 106: 87-103
26. Kessler J, Thiel A, Karbe H, Heiss WD (2000) Piracetam improves activated blood flow and facilitates rehabilitation of poststroke aphasic patients. Stroke 31: 2112-2116
27. Kopanitsa MV, Krishtal OA, Komissarov IV (2000) Inhibitory action of ambocarb on voltage-operated sodium channels in rat isolated hippocampal pyramidal neurons. Clin Exp Pharmacol Physiol 27: 46-54
28. Krall RL, Penry JK, White BG, Kupferberg HJ, Swinyard EA (1978) Antiepileptic drug development. II. Anticonvulsant drug screening. Epilepsia 19: 409-428
29. Kunneke PS, Malan GM (1979) A controlled clinical trial on the effect of piracetam in epileptic children. Br J Clin Pract 33: 266-271
30. Kwan P, Brodie MJ (2001) Neuropsychological effects of epilepsy and antiepileptic drugs. Lancet 357: 216-222
31. Litchfield JT Jr, Wilcoxon F (1949) A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 96: 99-113
32. Löscher W, Schmidt D (1988) Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res 2: 145-181
33. Löscher W, Hönack D (1993) Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur J Pharmacol 232: 147-158
34. Löscher W, Schmidt D (2002) New horizons in the development of antiepileptic drugs. Epilepsy Res 50: 3-16
35. Louchahi K, Tod M, Bonnardel P, Petitjean O (1995) Determination of piracetam in human plasma and urine by liquid chromatography. J Chromatogr B Biomed Appl 663: 385-389
36. Mareš P (1989) Piracetam and metrazol-induced ECoG phenomena. Activ Nerv Sup (Praha) 31: 67-68
37. Meinardi H (1993) Epidemiology of epilepsy. Tropic Geograph Med 45: 218-221
38. Mondadori C, Schmutz M (1986) Synergistic effects of oxiracetam and piracetam in combination with antiepileptic drugs. Acta Neurol Scand 74 [Suppl 109]: 113-116
39. Mondadori C, Schmutz M, Baltzer V (1984) Potentiation of the anticonvulsant effects of antiepileptic drugs by "nootropics"; a potential new therapeutic approach. Acta Neurol Scand 69 [Suppl 99]: 131-132
40. Morgenstern E, Stattmann A, Voigt JP (1989) Influence of piracetam on anticonvulsant effects of antiepileptic drugs in mice. Activ Nerv Sup (Praha) 32: 55-56
41. Moyersoons F, Evraerd A, Dauby J, Giurgea C (1969) A particular pharmacological effect on the propagation of experimental strychnine and penicillin epilepsy. Arch Int Pharmacodyn 179: 388-400
42. Müller WE, Koch S, Scheuer K, Rostock A, Bartsch R (1997) Effects of piracetam on membrane fluidity in the aged mouse, rat and human brain. Biochem Pharmacol 53: 135-140
43. Müller WE, Eckert GP, Eckert A (1999) Piracetam: novelty in a unique mode of action. Pharmacopsychiat 32 [Suppl]: 2-9
44. Nicholson CD (1990) Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia. Psychopharmacology 101: 147-159
45. Obeso JA, Artieda J, Luquin MR, Vaamonde J, Martinez Lage JM (1986) Antimyoclonic action of piracetam. Clin Neuropharmacol 9: 58-64
46. Olpe H-R, Steinmann MW (1982) The effect of vincamine, hydergine and piracetam on the firing rate of Locus coeruleus neurons. J Neural Transm 55: 101-109
47. 31P nuclear magnetic resonance and conformational analysis. Biochem Pharmacol 50: 1129-1134
48. Pranzatelli MR, Nadi NS (1995) Mechanism of action of antiepileptic and antimyoclonic drugs. Adv Neurol 67: 329-360
49. Rahmann A, Stodieck S, Husstedt I-W, Evers S (2002) Pre-attentive cognitive processing in epilepsy. A pilot study on the impact of epilepsy type and anti-epileptic treatment. Eur Neurol 48: 146-152
50. Russo E, Constanti A, Ferreri G, Citraro R, De Sarro G (2003) Nifedipine affects the anticonvulsant activity of topiramate in various animal models of epilepsy. Neuropharmacology 46: 865-878
51. Sander JWAS, Shorvon SD (1996) Epidemiology of the epilepsies. J Neurol Neurosurg Psychiatry 61: 433-443
52. Sareen D (2002) Neuroprotective agents in acute ischemic stroke. J Assoc Phys India 50: 250-258
53. Sarter M (1991) Taking stock of cognition enhancers. Trends Pharmacol Sci 12: 456-461
54. Scheibler P, Kittner H (1996) Influence of piracetam and vinpocetine on brain concentrations of some antiepileptics in rats. Pharm Pharmacol Lett 6: 68-69
55. Schmidt J (1987) New aspects in the pharmacology of kindling. Implications for mechanism of action in kindling. Pol J Pharmacol Pharm 39: 527-536
56. Schmidt J (1990) Comparative studies on the anticonvulsant effectiveness of nootropic drugs in kindled rats. Biomed Biochim Acta 49: 413-419
57. Schwartzkroin PA, Wyler AR (1980) Mechanisms underlying epileptiform burst discharge. Ann Neurol 7: 95-107
58. Solntseva EI, Bukanova JV, Ostrovskaya RU, Gudasheva TA, Voronina TA, Skrebitsky VG (1997) The effects of piracetam and its novel peptide analogue GVS-111 on neuronal voltage-gated calcium and potassium channels. Gen Pharmac 29: 85-89
59. Speckmann E-J, Straub H, Köhling R (1993) Contribution of calcium ions to the generation of epileptic activity and antiepileptic calcium antagonism. Neuropsychobiology 27: 122-126
60. Stancheva SL, Petkov VD, Hadjiivanova CI, Petkov VV (1991) Age-related changes of the effects of a group of nootropics drugs on the content of rat brain biogenic monoamines. Gen Pharmac 22: 873-877
61. Swinyard EA, Brown WC, Goodman LS (1952) Comparative assays of antiepileptic drugs in mice and rats. J Pharmacol Exp Ther 106: 319-330
62. Tacconi MT, Wurtman RJ (1986) Piracetam: physiological disposition and mechanism of action. Adv Neurol 43: 675-685
63. Tariska P, Paksy A (2000) A piracetam tünetjavíitó hatása enyhe kognitív zavar és demencia tünetcsoportjában szenvedö betegeken (Cognitive enhancement effect of piracetam in patients with mild cognitive impairment and dementia). Orv Hetil 141: 1189-1193
64. Trimble MR (1987) Anticonvulsant drugs and cognitive function: a review of the literature. Epilepsia 28 [Suppl 3]: S37-S45
65. Tsolaki M, Pantazi T, Kazis A (2001) Efficacy of acetylcholinesterase inhibitors versus nootropics in Alzheimer's disease: a retrospective, longitudinal study. J Int Med Res 29: 28-36
66. Uthman BM, Reichl A (2002) Progressive myoclonic epilepsy. Curr Treatm Opt Neurol 4: 3-17
67. Vernon MW, Sorkin EM (1991) Piracetam. An overview of its pharmacological properties and a review of its therapeutic use in senile cognitive disorders. Drugs & Aging 1: 17-35
68. Voigt J-P, Morgenstern E (1988) Nootropika und Epilepsien. Pharmazie 43: 673-676
69. Waegemans T, Wilsher CR, Danniau A, Ferris SH, Kurz A, Winblad B (2002) Clinical efficacy of piracetam in cognitive impairment: a meta-analysis. Dement Geriatr Cogn Disord 13: 217-224
70. i increase in rat hippocampal CA1 pyramidal cells. Neurochem Res 26: 1095-1100